Traveler’s Diarrhea Treatment Market

Traveler’s Diarrhea Treatment Market (Drug Class: Oral Rehydration Therapy (ORS), Antidiarrheal Agents, Antibiotics [Azithromycin, Ciprofloxacin, Quinolones, and Rifaximi], Vaccines/Prophylactics, and Others; Pathogen: Bacteria [E. Coli, Salmonella Spp, and Others], Viruses, and Protozoa; Age Group: Adults and Children; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Travelers Seek Solutions to Counter Diarrheal Pathogens in Tropical Regions

International travel has gained significant momentum in the past decade and the trend is showing no signs of slowing down. As per the data released by the World Tourism Organization (UNWTO), an astounding 1.4 billion international tourist arrivals were recorded - a 6% rise from 2017. As per the observable trends, tourists are traveling in huge numbers to tropical and sub-tropical countries, including Thailand, Spain, and India. However, tourists are at a high risk of being exposed to diarrheal pathogens in these regions and thus, traveler’s diarrhea has emerged as one of the most common health problems faced by international travelers.

Traditionally, antibiotic prophylaxis is used to prevent traveler’s diarrhea, which is primarily caused by bacterial etiologies. The traveler’s diarrhea treatment market is expanding at a rapid pace, as awareness among travelers related to ill effects of traveler’s diarrhea is increasing. Furthermore, drug approvals by the FDA, rise in the number of research activities, and development of new therapeutics are some of the leading factors that are expected to drive the traveler’s diarrhea treatment market. The market for traveler’s diarrhea treatment is expected to reach a value of ~US$ 1.3 Bn by 2027.

travelers diarrhea treatment market infographic

Request a sample to get extensive insights into the Traveler’s Diarrhea Treatment Market 

FDA Approvals for New Drugs for Treatment of Traveler’s Diarrhea

Antibiotics used to treat and manage traveler’s diarrhea have evolved at a rapid pace in the past 50 years due to a range of factors, including drug resistance, costs, and side-effects. However, with consistent developments in research, new and improved treatments for traveler’s diarrhea are entering the traveler’s diarrhea treatment market.

The Food and Drug Administration (FDA) has given approval to several new treatments and drugs in recent years. For instance, Aemcolo, an oral antibacterial rifamycin, was approved by the FDA in November 2018 to treat traveler’s diarrhea caused by E.coli. Clinical studies have revealed that rifamycin has greater efficiency in reducing the symptoms of diarrhea symptoms compared to placebo. Antibiotics are primarily recommended to treat severe traveler’s diarrhea. Despite a few side effects, within the drug class segment, antibiotics are likely to stay ahead with a market share of ~51% during the forecast period. The management and treatment of traveler’s diarrhea are expected to evolve, owing to the formulation of different guidelines laid down by regulatory bodies worldwide. As per the new guidelines, the use of antibiotics for mild traveler’s diarrhea is not recommended, as they have been linked to adverse events.

Antidiarrheal agents, such as bismuth subsalicylate and loperamide, are predominantly used in conjunction with antibiotics to offer instant relief from the symptoms of traveler’s diarrhea. The treatment of traveler’s diarrhea primarily depends on the severity of the treatment. Oral rehydration solutions are ideally used to treat traveler’s diarrhea in children, infants, and geriatric population, as these patients are more susceptible to dehydration and electrolyte imbalance. The oral rehydration solution and antidiarrheal segments of the traveler’s diarrhea treatment market are collectively expected to reach a value of ~US$ 511 Mn by the end of 2027.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Bacteria to Retain Lead as Primary Traveler’s Diarrhea-causing Pathogen

Traveler’s diarrhea is predominantly caused by pathogens such as viruses, bacteria, and protozoa. Of these, nearly 80% of the cases are caused by bacteria, and thus, this segment is projected to account for ~ 69% share of the traveler’s diarrhea treatment market in 2019. Viruses are the causative agents for ~5-10% cases depending on geographical location. As per the Centers for Disease Control and Prevention data, norovirus and rotavirus are the leading types of viruses that cause traveler’s diarrhea. E.coli and Salmonella Spp are the two major bacteria types responsible for traveler’s diarrhea. According to the British Medical Journal, the prevalence of traveler’s diarrhea is higher among travelers visiting regions in South Asia and Southeast Asia. Thus, the traveler’s diarrhea treatment market is expected to grow during the forecast period.

travelers diarrhea treatment market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on “Traveler’s Diarrhea Treatment Market”

Analysts’  Viewpoint

The traveler’s diarrhea treatment market is expected to expand at a healthy CAGR of ~7% during the forecast period. Development of new drugs, growing awareness among travelers, and approval from the FDA will continue to play an imperative role in the growth of the traveler’s diarrhea treatment market in the near future. Companies in the traveler’s diarrhea treatment market landscape should focus on the development of new drugs and ensure they are compliant with the current guidelines. Among regions, with a market share of ~42% in 2018, North America will retain its lead during the forecast period, owing to product approvals and early adoption of new products. 

Traveler’s Diarrhea Treatment Market: Overview

  • According to Transparency Market Research’s latest market report on the traveler’s diarrhea treatment market for the historical period of 2017 - 2018 and forecast period of 2019 - 2027, a surge in the number of travelers and rise in awareness among travelers about traveler’s diarrhea is anticipated to drive the traveler’s diarrhea treatment market
  • According to the report, the global traveler’s diarrhea treatment market was valued at ~US$ 738 Mn in 2018. It is projected to expand at a CAGR of ~7% from 2019 to 2027

Surge in Number of Travelers and Awareness Among Travelers: A Key Driver

  • The risk of acquiring traveler’s diarrhea is high in developing countries such as those in Africa, the Middle East, Asia, and Latin America. Increase in number of travelers to developing countries in these regions is driving the number of traveler’s diarrhea patients.
  • For instance, according to The World Tourism Organization (UNWTO), in 2018, estimated international tourist arrivals (overnight visitors) increased 6% to 1.4 billion across the world
  • According to the worldatlas, Southeast Asia receives the highest number of travelers and an estimated 55.6 million people visited China, Thailand received 24.8 million visitors, South Korea welcomed 14.2 million, Japan 13.4 million, and Indonesia received 10.4 million visitors annually
  • As per the Center for Disease Control and Prevention (CDC), in 2016, more than 6 million international travelers visited Brazil
  • Rise in number of travelers is boosting travel expenditure. For instance, according to The U.S. Travel Association, in the U.S., an estimated US$ 1.1 trillion was spent by domestic and international inbound travelers.
  • Rise in awareness among travelers is anticipated to drive the global traveler’s diarrhea treatment market. For instance, pre-travel counseling is essential, due to a rise in number of travelers and knowledge related to traveler’s medicine. The goal of pre-travel consultation is to improve the understanding of travelers about travel-related health hazards and diseases.
  • The number of international travelers has been increasing at a steady pace, and travel-related health issues are rising frequently

Development of New Treatments

  • Antibiotics is a widely prescribed treatment for traveler’s diarrhea. Antibiotics such as ciprofloxacin, quinolones azithromycin, and rifaximin are prescribed for the treatment of traveler’s diarrhea.
  • However, overuse of antibiotics leads to antibiotic resistance. Thus, new antibiotics are being introduced to overcome microbial resistance by antibiotics and make the traveler’s diarrhea treatment effective
  • Increase in prevalence of infectious diseases, such as diarrhea and traveler’s diarrhea, is fueling the demand for new development of treatment. Consequently, numerous clinical trials are conducted in order to develop safe and effective treatment. For instance, clinical trial was conducted in Bangladesh for inactivated vaccine candidate against enterotoxigenic E. coli, and it was found to be safe in children and adults for the treatment of diarrhea.
  • Industry players are focused on research and development to introduce new therapeutic products for the treatment of traveler’s diarrhea
  • Thus, the new development of treatment for traveler’s diarrhea is likely fuel the global market

Trend of Self-medication Using OTC Products and Misuse of Antibiotics Hamper Traveler’s Diarrhea Treatment Market

  • Increase in use of over the counter medication for the treatment of traveler’s diarrhea is anticipated to hamper the market. For instance, according to an article published in The Journal of Life and Environmental Sciences, the study conducted during 2013-2014 in China Mainland, the estimated rate of antibiotic misuse was 35.12%
  • Rise in use of antibiotics increases the risk of antibiotic resistance. Therefore, as per WHO guidelines, the use of antibiotics is restricted to cholera with severe dehydration and bloody diarrhea.

Traveler’s Diarrhea Treatment Market: Competition Landscape

  • This report profiles major players in the global traveler’s diarrhea treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global traveler’s diarrhea treatment market is moderately fragmented, with presence of a few large-scale players in international markets and several small-scale players in regional markets. Top 4 to 5 players hold a major share of the global traveler’s diarrhea treatment market.
  • Prominent players operating in the global traveler’s diarrhea treatment market include -
    • Johnson & Johnson (Johnson & Johnson Consumer Inc.)
    • Bausch Health Companies Inc. (Salix Pharmaceuticals)
    • COSMO PHARMACEUTICALS
    • Immuron
    • Valneva SE
    • Sun Pharmaceutical Industries Ltd.
    • Norgine
    • Perrigo Company plc
    • Bayer AG

Global Traveler’s Diarrhea Treatment Market: Key Developments

Key players in the global traveler’s diarrhea treatment market are engaged in the development of new products and approvals, merger & acquisitions, and collaborations. Strategies adopted by key players are likely to boost the global traveler’s diarrhea treatment market. Major strategies adopted by the players in the traveler’s diarrhea treatment market are:

  • In October 2019, Bausch Health Companies Inc. announced the receipt of the U.S. patent and Trademark patent covering use of XIFAXAN. This enabled the company to strengthen the intellectual property of XIFAXAN.
  • In October 2019, COSMO PHARMACEUTICALS announced a licensing agreement with RedHill Biopharma for Aemcolo for the U.S. This enabled COSMO PHARMACEUTICALS to be an exclusive supplier of Aemcolo.
  • In April 2019, Health Canada approved Travelan in Canada
  • In November 2018, COSMO PHARMACEUTICALS received U.S. Food and Drug Administration approval for Aemcolo for the treatment of traveler’s diarrhea

The report on the global traveler’s diarrhea treatment market discusses individual strategies, followed by company profiles of manufacturers of traveler’s diarrhea treatment products. The competitive landscape section is included in the traveler’s diarrhea treatment report to provide readers with a dashboard view and a company market share analysis of key players operating in the global traveler’s diarrhea treatment market.

Traveler’s Diarrhea Treatment Market - Segmentation

Drug Class

  • Oral Rehydration Therapy (ORS)
  • Antidiarrheal Agents
  • Antibiotics
    • Azithromycin
    • Ciprofloxacin
    • Quinolones
    • Rifaximi
  • Vaccines/Prophylactics
  • Others

Pathogen

  • Bacteria
    • E. Coli
    • Salmonella Spp
    • Others
  • Viruses
  • Protozoa
    • Giardiasis
    • Cryptosporidium parvum

Age Group

  • Adults
  • Children

Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of traveler’s diarrhea treatment market?

Traveler’s diarrhea treatment market is expected to reach a value of ~US$ 1.3 Bn by 2027

What is the anticipated CAGR of the traveler’s diarrhea treatment market in the forecast period?

Traveler’s diarrhea treatment market is projected to expand at a CAGR of ~7% from 2019 to 2027

What are the key driving factors for the growth of the traveler’s diarrhea treatment market?

Traveler’s diarrhea treatment market is driven by surge in the number of travelers and rise in awareness among travelers about traveler’s diarrhea

Which region is expected to project the highest market share in the global traveler’s diarrhea treatment market?

North america accounted for a major share of the global traveler’s diarrhea treatment market

Who are the key players in the traveler’s diarrhea treatment market?

Key players in the global traveler’s diarrhea treatment market include Johnson & Johnson (Johnson & Johnson Consumer Inc.), Bausch Health Companies Inc. (Salix Pharmaceuticals), COSMO PHARMACEUTICALS, Immuron, Valneva SE

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Traveler’s Diarrhea Treatment Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Drug Class Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

                4.3.1.1. Surge in Number of Travelers

                4.3.1.2. Awareness Among Travelers 

                4.3.1.3. Evolution of Pathogens and Antimicrobial Resistance

                4.3.1.4. Rise in Number of Food Contamination Cases

                4.3.1.5. New Therapeutics in Development

            4.3.2. Restraints

                4.3.2.1. Trend of Self-medication Using OTC Products and Misuse of Antibiotics

                4.3.2.2. Awareness about Hygiene 

                4.3.2.3. Introduction of Generic Products

            4.3.3. Opportunities

        4.4. Global Traveler’s Diarrhea Treatment Market Analysis and Forecasts, 2017–2027

    5. Market Outlook

        5.1. Overview of Guidelines for Diagnosis & Treatment of Traveler’s Diarrhea 

        5.2. Private/Public Sector Drug Supply Chain by Region/Country

        5.3. Pipeline Analysis

        5.4. Epidemiology of Traveler’s Diarrhea by Region/Sub-region

        5.5. Overview of Causes/Percentage of Bacteria, Viruses and Protozoa Causing Traveler’s Diarrhea 

    6. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Drug Class  

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class, 2017–2027

            6.3.1. Oral Rehydration Therapy (ORS)

            6.3.2. Antidiarrheal Agents

                6.3.2.1. Antibiotics

                6.3.2.2. Azithromycin

                6.3.2.3. Ciprofloxacin

                6.3.2.4. Quinolones

                6.3.2.5. Rifaximin

            6.3.3. Vaccines/prophylactics

            6.3.4. Others

        6.4. Global Traveler’s Diarrhea Treatment Market Attractiveness, by Drug Class  

    7. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Pathogen

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2027

            7.3.1. Bacteria

                7.3.1.1. E. Coli

                7.3.1.2. Salmonella Spp

                7.3.1.3. Others

            7.3.2. Viruses

            7.3.3. Protozoa 

                7.3.3.1. Giardiasis

                7.3.3.2. Cryptosporidium parvum

        7.4. Global Traveler’s Diarrhea Treatment Market Attractiveness, by Pathogen

    8. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Age 

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2027

            8.3.1. Adults 

            8.3.2. Children

        8.4. Global Traveler’s Diarrhea Treatment Market Attractiveness, by Age 

    9. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Distribution Channel 

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2027

            9.3.1. Retail Pharmacies

            9.3.2. Hospital Pharmacies

            9.3.3. Online Pharmacies

        9.4. Global Traveler’s Diarrhea Treatment Market Attractiveness, by Distribution Channel 

    10. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Region

            10.2.1. North America 

            10.2.2. Europe 

            10.2.3. Asia Pacific 

            10.2.4. Latin America 

            10.2.5. Middle East & Africa 

        10.3.  Global Traveler’s Diarrhea Treatment Market Attractiveness, by Region

    11. North America Traveler’s Diarrhea Treatment Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class , 2017–2027

            11.2.1. Oral Rehydration Therapy (ORS)

            11.2.2. Antidiarrheal Agents

            11.2.3. Antibiotics

                11.2.3.1. Azithromycin

                11.2.3.2. Ciprofloxacin

                11.2.3.3. Quinolones

                11.2.3.4. Rifaximin

            11.2.4. Vaccines/prophylactics

            11.2.5. Others

        11.3. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2027

            11.3.1. Bacteria

                11.3.1.1. E. Coli

                11.3.1.2. Salmonella Spp

                11.3.1.3. Others

            11.3.2. Viruses

            11.3.3. Protozoa 

                11.3.3.1. Giardiasis

                11.3.3.2. Cryptosporidium parvum

        11.4. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2027

            11.4.1. Adults 

            11.4.2. Children

        11.5. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2027

            11.5.1. Retail Pharmacies

            11.5.2. Hospital Pharmacies

            11.5.3. Online Pharmacies

        11.6. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Country, 2017–2027

            11.6.1. U.S.

            11.6.2. Canada

        11.7. North America Traveler’s Diarrhea Treatment Market Attractiveness Analysis 

            11.7.1. By Drug Class  

            11.7.2. By Pathogen

            11.7.3. By Age 

            11.7.4. By Distribution Channel 

            11.7.5. By Country

    12. Europe Traveler’s Diarrhea Treatment Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class , 2017–2027

            12.2.1. Oral Rehydration Therapy (ORS)

            12.2.2. Antidiarrheal Agents

            12.2.3. Antibiotics

                12.2.3.1. Azithromycin

                12.2.3.2. Ciprofloxacin

                12.2.3.3. Quinolones

                12.2.3.4. Rifaximin

            12.2.4. Vaccines/prophylactics

            12.2.5. Others

        12.3. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2027

            12.3.1. Bacteria

                12.3.1.1. E. Coli

                12.3.1.2. Salmonella Spp

                12.3.1.3. Others

            12.3.2. Viruses

            12.3.3. Protozoa 

                12.3.3.1. Giardiasis

                12.3.3.2. Cryptosporidium parvum

        12.4. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2027

            12.4.1. Adults 

            12.4.2. Children

        12.5. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2027

            12.5.1. Retail Pharmacies

            12.5.2. Hospital Pharmacies

            12.5.3. Online Pharmacies

        12.6. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Europe Traveler’s Diarrhea Treatment Market Attractiveness Analysis 

            12.7.1. By Drug Class  

            12.7.2. By Pathogen

            12.7.3. By Age 

            12.7.4. By Distribution Channel 

            12.7.5. By Country/Sub-region

    13. Asia Pacific Traveler’s Diarrhea Treatment Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class, 2017–2027

            13.2.1. Oral Rehydration Therapy (ORS)

            13.2.2. Antidiarrheal Agents

            13.2.3. Antibiotics

                13.2.3.1. Azithromycin

                13.2.3.2. Ciprofloxacin

                13.2.3.3. Quinolones

                13.2.3.4. Rifaximin

            13.2.4. Vaccines/prophylactics

            13.2.5. Others

        13.3. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2027

            13.3.1. Bacteria

                13.3.1.1. E. Coli

                13.3.1.2. Salmonella Spp

                13.3.1.3. Others

            13.3.2. Viruses

            13.3.3. Protozoa 

                13.3.3.1. Giardiasis

                13.3.3.2. Cryptosporidium parvum

        13.4. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2027

            13.4.1. Adults 

            13.4.2. Children

        13.5. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2027

            13.5.1. Retail Pharmacies

            13.5.2. Hospital Pharmacies

            13.5.3. Online Pharmacies

        13.6. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Asia Pacific Traveler’s Diarrhea Treatment Market Attractiveness Analysis 

            13.7.1. By Drug Class  

            13.7.2. By Pathogen

            13.7.3. By Age 

            13.7.4. By Distribution Channel 

            13.7.5. By Country/Sub-region

    14. Latin America Traveler’s Diarrhea Treatment Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Latin America Traveler’s Diarrhea Market Value Forecast, by Drug Class , 2017–2027

            14.2.1. Oral Rehydration Therapy (ORS)

            14.2.2. Antidiarrheal Agents

            14.2.3. Antibiotics

                14.2.3.1. Azithromycin

                14.2.3.2. Ciprofloxacin

                14.2.3.3. Quinolones

                14.2.3.4. Rifaximin

            14.2.4. Vaccines/prophylactics

            14.2.5. Others

        14.3. Latin America Traveler’s Diarrhea Market Value Forecast, by Pathogen, 2017–2027

            14.3.1. Bacteria

                14.3.1.1. E. Coli

                14.3.1.2. Salmonella Spp

                14.3.1.3. Others

            14.3.2. Viruses

            14.3.3. Protozoa 

                14.3.3.1. Giardiasis

                14.3.3.2. Cryptosporidium parvum

        14.4. Latin America Traveler’s Diarrhea Market Value Forecast, by Age, 2017–2027

            14.4.1. Adults 

            14.4.2. Children

        14.5. Latin America Traveler’s Diarrhea Market Value Forecast, by Distribution Channel, 2017–2027

            14.5.1. Retail Pharmacies

            14.5.2. Hospital Pharmacies

            14.5.3. Online Pharmacies

        14.6. Latin America Traveler’s Diarrhea Market Value Forecast, by Country/Sub-region, 2017–2027

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Latin America Traveler’s Diarrhea Market Attractiveness Analysis 

            14.7.1. By Drug Class  

            14.7.2. By Pathogen

            14.7.3. By Age 

            14.7.4. By Distribution Channel 

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Traveler’s Diarrhea Treatment Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class , 2017–2027

            15.2.1. Oral Rehydration Therapy (ORS)

            15.2.2. Antidiarrheal Agents

            15.2.3. Antibiotics

                15.2.3.1. Azithromycin

                15.2.3.2. Ciprofloxacin

                15.2.3.3. Quinolones

                15.2.3.4. Rifaximin

            15.2.4. Vaccines/prophylactics

            15.2.5. Others

        15.3. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2027

            15.3.1. Bacteria

                15.3.1.1. E. Coli

                15.3.1.2. Salmonella Spp

                15.3.1.3. Others

            15.3.2. Viruses

            15.3.3. Protozoa 

                15.3.3.1. Giardiasis

                15.3.3.2. Cryptosporidium parvum

        15.4. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2027

            15.4.1. Adults 

            15.4.2. Children

        15.5. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2027

            15.5.1. Retail Pharmacies

            15.5.2. Hospital Pharmacies

            15.5.3. Online Pharmacies

        15.6. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Middle East & Africa Traveler’s Diarrhea Treatment Market Attractiveness Analysis 

            15.7.1. By Drug Class  

            15.7.2. By Pathogen

            15.7.3. By Age 

            15.7.4. By Distribution Channel 

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player - Competition Matrix (By Tier and Size of companies)

        16.2. Market Share Analysis/Ranking By Company (2018)

        16.3. Company Profiles

            16.3.1. Johnson & Johnson (Johnson & Johnson Consumer Inc.)

                16.3.1.1. Company Overview

                16.3.1.2. Company Financials

                16.3.1.3. Growth Strategies

                16.3.1.4. SWOT Analysis

            16.3.2. Bausch Health Companies Inc. (Salix Pharmaceuticals)

                16.3.2.1. Company Overview

                16.3.2.2. Company Financials

                16.3.2.3. Growth Strategies

                16.3.2.4. SWOT Analysis

            16.3.3. COSMO PHARMACEUTICALS

                16.3.3.1. Company Overview

                16.3.3.2. Company Financials

                16.3.3.3. Growth Strategies

                16.3.3.4. SWOT Analysis 

            16.3.4. Immuron

                16.3.4.1. Company Overview

                16.3.4.2. Company Financials

                16.3.4.3. Growth Strategies

                16.3.4.4. SWOT Analysis

            16.3.5. Valneva SE

                16.3.5.1. Company Overview

                16.3.5.2. Company Financials

                16.3.5.3. Growth Strategies

                16.3.5.4. SWOT Analysis

            16.3.6. Sun Pharmaceutical Industries Ltd.

                16.3.6.1. Company Overview

                16.3.6.2. Company Financials

                16.3.6.3. Growth Strategies

                16.3.6.4. SWOT Analysis

            16.3.7. Norgine

                16.3.7.1. Company Overview

                16.3.7.2. Company Financials

                16.3.7.3. Growth Strategies

                16.3.7.4. SWOT Analysis

            16.3.8. Perrigo Company plc

                16.3.8.1. Company Overview

                16.3.8.2. Company Financials

                16.3.8.3. Growth Strategies

                16.3.8.4. SWOT Analysis

            16.3.9. Bayer AG

                16.3.9.1. Company Overview

                16.3.9.2. Company Financials

                16.3.9.3. SWOT Analysis

    List of Tables

    Table 01: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 02: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2027

    Table 03: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027

    Table 04: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Bacteria, 2017–2027

    Table 05: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Protozoa, 2017–2027

    Table 06: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Age, 2017–2027

    Table 07: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 08: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

    Table 09: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 10: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2027

    Table 11: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027

    Table 12: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Bacteria 2017–2027

    Table 13: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Protozoa 2017–2027

    Table 14: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Age 2017–2027

    Table 15: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 16: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 17: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 18: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2027

    Table 19: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027

    Table 20: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Bacteria 2017–2027

    Table 21: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Protozoa 2017–2027

    Table 22: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Age 2017–2027

    Table 23: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 24: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 25: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 26: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2027

    Table 27: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027

    Table 28: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Bacteria 2017–2027

    Table 29: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Protozoa 2017–2027

    Table 30: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Age 2017–2027

    Table 31: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 32: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 33: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 34: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2027

    Table 35: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027

    Table 36: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Bacteria 2017–2027

    Table 37: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Protozoa 2017–2027

    Table 38: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Age 2017–2027

    Table 39: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 40: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 41: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 42: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2027

    Table 43: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027

    Table 44: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Bacteria 2017–2027

    Table 45: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Protozoa 2017–2027

    Table 46: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Age 2017–2027

    Table 47: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 48: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    List of Figures

    Figure 01: Global Traveler’s Diarrhea Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027

    Figure 02: Global Traveler’s Diarrhea Treatment Market Value (US$ Mn), by Drug Class, 2018

    Figure 03: Global Traveler’s Diarrhea Treatment Market Value Share Analysis by Pathogen, 2018

    Figure 04: Market Overview

    Figure 05: Global Traveler’s Diarrhea Treatment Market Value Share, by Drug Class, 2018

    Figure 06: Global Traveler’s Diarrhea Treatment Market Value Share, by Pathogen, 2018

    Figure 07: Global Traveler’s Diarrhea Treatment Market Value Share, by Age, 2018

    Figure 08: Global Traveler’s Diarrhea Treatment Market Value Share, by Distribution Channel, 2018

    Figure 09: Global Traveler’s Diarrhea Treatment Market Value Share, by Region, 2018

    Figure 10: Global Traveler’s Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

    Figure 11: Global Traveler's Diarrhea Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 12: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Oral Rehydration Therapy (ORS), 2017–2027

    Figure 13: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Antidiarrheal Agents, 2017–2027

    Figure 14: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Antibiotics, 2017–2027

    Figure 15: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Vaccines/prophylactics, 2017–2027

    Figure 16: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2017–2027

    Figure 17: Global Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

    Figure 18: Global Traveler's Diarrhea Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027

    Figure 19: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Bacteria, 2017–2027

    Figure 20: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Viruses, 2017–2027

    Figure 21: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Protozoa, 2017–2027

    Figure 22: Global Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Pathogen, 2019–2027

    Figure 23: Global Traveler's Diarrhea Treatment Market Value Share Analysis, by Age, 2018 and 2027

    Figure 24: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Adults, 2017–2027

    Figure 25: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Children, 2017–2027

    Figure 26: Global Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Age, 2019–2027

    Figure 27: Global Traveler's Diarrhea Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 28: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies, 2017–2027

    Figure 29: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Hospital Pharmacies, 2017–2027

    Figure 30: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Online Pharmacies, 2017–2027

    Figure 31: Global Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 32: Global Traveler's Diarrhea Treatment Market Value Share Analysis, by Region, 2018 and 2027

    Figure 33: Global Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Region, 2019–2027

    Figure 34: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 35: North America Traveler's Diarrhea Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 36: North America Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

    Figure 37: North America Traveler's Diarrhea Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027

    Figure 38: North America Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Pathogen, 2019–2027

    Figure 39: North America Traveler's Diarrhea Treatment Market Value Share Analysis, by Age, 2018 and 2027

    Figure 40: North America Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Age, 2019–2027

    Figure 42: North America Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 -2027

    Figure 41: North America Traveler's Diarrhea Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 44: North America Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Country, 2019–2027

    Figure 43: North America Traveler's Diarrhea Treatment Market Value Share Analysis, by Country, 2018 and 2027

    Figure 45: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 46: Europe Traveler's Diarrhea Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 47: Europe Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

    Figure 48: Europe Traveler's Diarrhea Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027

    Figure 49: Europe Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Pathogen, 2019–2027

    Figure 50: Europe Traveler's Diarrhea Treatment Market Value Share Analysis, by Age, 2018 and 2027

    Figure 51: Europe Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Age, 2019–2027

    Figure 52: Europe Traveler's Diarrhea Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 53: Europe Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 -2027

    Figure 54: Europe Traveler's Diarrhea Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 55: Europe Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 56: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 57: Asia Pacific Traveler's Diarrhea Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 58: Asia Pacific Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

    Figure 59: Asia Pacific Traveler's Diarrhea Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027

    Figure 60: Asia Pacific Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Pathogen, 2019–2027

    Figure 61: Asia Pacific Traveler's Diarrhea Treatment Market Value Share Analysis, by Age, 2018 and 2027

    Figure 62: Asia Pacific Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Age, 2019–2027

    Figure 63: Asia Pacific Traveler's Diarrhea Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 64: Asia Pacific Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 -2027

    Figure 65: Asia Pacific Traveler's Diarrhea Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 66: Asia Pacific Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 67: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 68: Latin America Traveler's Diarrhea Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 69: Latin America Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

    Figure 70: Latin America Traveler's Diarrhea Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027

    Figure 71: Latin America Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Pathogen, 2019–2027

    Figure 72: Latin America Traveler's Diarrhea Treatment Market Value Share Analysis, by Age, 2018 and 2027

    Figure 73: Latin America Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Age, 2019–2027

    Figure 74: Latin America Traveler's Diarrhea Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 75: Latin America Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 -2027

    Figure 76: Latin America Traveler's Diarrhea Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 77: Latin America Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 78: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 79: Middle East & Africa Traveler's Diarrhea Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 80: Middle East & Africa Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

    Figure 81: Middle East & Africa Traveler's Diarrhea Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027

    Figure 82: Middle East & Africa Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Pathogen, 2019–2027

    Figure 83: Middle East & Africa Traveler's Diarrhea Treatment Market Value Share Analysis, by Age, 2018 and 2027

    Figure 84: Middle East & Africa Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Age, 2019–2027

    Figure 85: Middle East & Africa Traveler's Diarrhea Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 86: Middle East & Africa Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 -2027

    Figure 87: Middle East & Africa Traveler's Diarrhea Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 88: Middle East & Africa Traveler's Diarrhea Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Copyright © Transparency Market Research, Inc. All Rights reserved